ABMD beats, up big

As opposed to CRTO, ABMD impressed the street and is up 14%

7:10 am Abiomed beats by $0.13, beats on revs; guides FY16 revs above consensus (ABMD) : Reports Q1 (Jun) earnings of $0.20 per share, $0.13 better than the Capital IQ Consensus Estimate of $0.07; revenues rose 50.4% year/year to $73.4 mln vs the $66.03 mln consensus.

Co issues raised guidance for FY16, sees FY16 revs of $300-310 mln from $285-295 mln vs. $292.42 mln Capital IQ Consensus Estimate.